UiPath climbs today: Key reasons behind the rally

Traders Union
All News
Financial News
Uipath rises 5.48% today to $10.49

Highlights

UiPath reported fiscal Q3 2026 revenue of $411.11 million, up 15.9% year-over-year, and delivered its first GAAP operating income of $13 million.
Annualized recurring revenue reached $1.782 billion, growing 11%, underlining momentum for UiPath’s AI-driven automation and new healthcare sector AI offerings with Genzeon.
PATH trades at $10.49 below major moving averages, with strong resistance near $12.52 and a bearish trend confirmed by momentum indicators, despite a 5.48% intraday rebound.

Recurring revenue growth and AI advances drive improved sentiment post-earnings

UiPath reported fiscal Q3 2026 revenue of $411.11 million, an increase of 15.9% year-over-year, and recorded its first GAAP operating income of $13 million. The company's annualized recurring revenue reached $1.782 billion, showing 11% growth and highlighting increased adoption of its AI-driven automation solutions. UiPath also joined the Agentic AI Foundation as a Gold Member and launched new agentic AI offerings for the healthcare sector in partnership with Genzeon.

Anton Kharitonov, expert at Traders Union, sees persistent weakness in UiPath's technical posture. He notes the price trades below all major moving averages, confirming a sustained seller bias. Kharitonov highlights that despite news of GAAP profitability and increased recurring revenue, the stock faces key resistance near $12.52 and lacks confirmed support. Oversold technical readings may trigger a short-term bounce, but these are not enough to signal a trend reversal. "Until we see proof of sustained demand above $10.65, downside and sideways movement remain the main risks for PATH," he warns.

Viktoras Karapetjanc, expert at Traders Union, believes PATH’s fundamentals show notable progress. He emphasizes UiPath’s robust year-over-year revenue growth and its first GAAP operating profit, which reflect strong institutional adoption of its AI-driven automation. Karapetjanc points to the Gold Membership in the Agentic AI Foundation and the new healthcare partnership as drivers of future expansion. He sees these achievements setting the stage for medium-term upside as the company captures more AI opportunities. "PATH’s bullish structure remains intact long term — further growth can be expected as adoption accelerates," he affirms.

Parshwa Turakhiya, analyst, notes extreme short-term oversold signals for PATH. He observes that buyers have managed to lift the price near today’s intraday highs, but technical momentum remains fragile. Turakhiya focuses on sentiment-driven setups, suggesting a possible rebound if $10.65 resistance is overcome soon. Tight volatility bands warn of potential whipsaws for active traders. "A technical bounce is possible this week, but staying nimble is critical in the current environment," he advises.

Bearish momentum and oversold signals emerge amid unconfirmed support

The nearest dynamic resistance for PATH is marked by the Ichimoku Kijun line at $12.52, while support levels have not yet been confirmed below current prices. Technical indicators such as MACD and ADX on the daily chart signal persistent bearish momentum. The daily RSI at 25.93, along with oversold signals on the Stoch RSI, CCI, and BBP, point to conditions that could precede a technical rebound. Nonetheless, while buyers drove the price near the upper end of today's intraday range, divergences among momentum indicators suggest that a sustained reversal is not conclusively supported.

Previously it was reported that UiPath Inc. is exhibiting persistent bearish momentum, with its price trading below all major moving averages and key resistance identified at the Ichimoku Kijun. Technical indicators such as the MACD and ADX confirm the downtrend, while oversold signals from the RSI and other oscillators suggest limited near-term upside within a confined trading range.

Source of Data: PATH Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.